The mechanism of action of glatiramer acetate treatment in multiple sclerosis.
about
Cutaneous adverse events associated with disease-modifying treatment in multiple sclerosis: a systematic reviewInterferon beta versus glatiramer acetate for relapsing-remitting multiple sclerosisInterferon beta versus glatiramer acetate for relapsing-remitting multiple sclerosisDisease-modifying treatments for multiple sclerosis - a review of approved medicationsRisk Mitigation Strategies for Adverse Reactions Associated with the Disease-Modifying Drugs in Multiple SclerosisAnti-human herpesvirus 6A/B IgG correlates with relapses and progression in multiple sclerosisMacrophage-specific chemokines induced via innate immunity by amino acid copolymers and their role in EAEInfection risk in patients on multiple sclerosis therapeutics.Treating relapsing-remitting multiple sclerosis: therapy effects on brain atrophy.Immunological mechanism of action and clinical profile of disease-modifying treatments in multiple sclerosis.Classical immunomodulatory therapy in multiple sclerosis: how it acts, how it works.Immune regulation of multiple sclerosis by CD8+ T cellsChemotherapeutics in the treatment of multiple sclerosis.The role of immune cells, glia and neurons in white and gray matter pathology in multiple sclerosis.Male microchimerism in peripheral blood leukocytes from women with multiple sclerosis.Testing effects of glatiramer acetate and fingolimod in an infectious model of CNS immune surveillance.The therapeutic potential of HDAC inhibitors in the treatment of multiple sclerosisMultiple sclerosis: pathogenesis and treatment.Equivalent Gene Expression Profiles between Glatopa™ and Copaxone®.Comparison of standard 1.5 T vs. 3 T optimized protocols in patients treated with glatiramer acetate. A serial MRI pilot study.Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.Epigallocatechin-3-gallate: a useful, effective and safe clinical approach for targeted prevention and individualised treatment of neurological diseases?Multiple sclerosis: Five new things.Targeting Non-classical Myelin Epitopes to Treat Experimental Autoimmune EncephalomyelitisMultiple Sclerosis: Pathogenesis, Symptoms, Diagnoses and Cell-Based Therapy.Chemokines and chemokine receptors in multiple sclerosis.Translational research in neurology and neuroscience 2010: multiple sclerosisRestoring the balance between disease and repair in multiple sclerosis: insights from mouse models.Managing MS in a changing treatment landscape.Sieving treatment biomarkers from blood gene-expression profiles: a pharmacogenomic update on two types of multiple sclerosis therapy.Induction of immune tolerance in the treatment of rheumatoid arthritis.Glatiramer acetate for treatment of relapsing-remitting multiple sclerosis.Disease-specific therapy of idiopathic inflammatory demyelinating disorders.Multiple sclerosis: basic knowledge and new insights in perioperative management.Next-generation therapeutic solutions for age-related macular degeneration.Metabolic and safety issues for multiple sclerosis pharmacotherapy--opportunities for personalised medicine.How do we manage and treat a patient with multiple sclerosis at risk of tuberculosis?Biomaterial strategies for generating therapeutic immune responses.Glatiramer acetate antibodies, gene expression and disease activity in multiple sclerosis.Repeated sugammadex usage in a patient with multiple sclerosis: a case report.
P2860
Q22241795-1E9FF553-26A6-45D9-BA92-9303E816A38AQ24194800-ED14AB41-227F-46D2-9FA5-F8BDE5EA5960Q24234763-1427EF36-9206-4952-A7E5-37B9A4497424Q26777329-0349F5E8-30A7-40FD-A5A7-033BF25CC02EQ28087414-05982B6F-BD49-4883-B83E-4E262104D95DQ28245682-891EC279-B92D-4E11-A2AC-5C77FA1CC3C6Q28741374-29C33869-21B8-42E1-8A2F-757739A3019EQ30908652-9D53B71A-9928-4828-A6BF-C758B2764A3AQ30965003-7884E882-F8F9-46D5-9004-48E44ED24A2EQ33755345-785AFB2D-BED1-4BF0-9B8E-88D29497BE15Q33960392-23599190-025B-4F77-A7B6-925695E29CDFQ34017004-838E8DEC-A44D-4DB1-B7F4-F63A73344A10Q34409536-94CFC325-5071-4F26-AA9D-63EC98615E0BQ34468304-89762B88-F9AA-4C85-8851-923EDED48AAFQ34890939-BA3902A9-B90D-42E5-8DA4-5400196F3937Q34976743-217255CA-357F-4632-A537-2B93F4A5BD53Q35016997-8D6FFAA2-274A-4894-A96A-B52718C57B6CQ35151851-237422C5-DD42-4953-8CF4-A1BEDE0BE0E3Q35810306-7C76E33C-91C4-4B26-AB0C-2FF999D00960Q36057186-DD8CABF0-C78F-432B-B90B-5859BD37B288Q36202727-998B59EB-6277-4F3F-B242-B34B7F6C2F78Q36648907-32015BB2-5F3D-46B1-8C78-BE9F09D014EEQ37251695-9A250D16-224D-43E9-8E87-3F8BE259A79DQ37379542-B6A0F72F-8D8A-4354-8959-C8939E5C0FC2Q37590908-06CBD37D-4F71-496F-A427-92ADB264AA96Q37594837-14656C78-20EE-43F3-B94F-D55F8D80551AQ37772026-1442E4DD-5751-4E96-978E-30BEAC1B0650Q37774489-8B06D196-B37E-449B-B6CE-1E856E9BA4D0Q37857752-16D6F00E-D7D3-49C0-B936-FB4D9524D157Q37859376-0D26F7CC-4139-4AFF-A8B0-80900FB9107AQ37862081-25BCDB20-3761-4460-900D-9238B0FC9B14Q37997089-15718151-BC9E-4B89-9693-F4754C08ECA1Q38049628-BAFE7FBE-EA38-4278-A746-92E3E63CD894Q38130445-0822239A-459D-4FF0-A6C9-44BBDCA647C1Q38138089-BF557AE7-AC68-4C85-8CCE-0942552412ECQ38218692-F7A402C5-E136-45EB-BEBA-FF0729A9E88BQ38252979-C167A0A9-43F2-4BB2-A339-EE6EA052563FQ39271088-D51FFC33-8552-4385-AA4F-58EB82E36AA6Q39694574-A2C6A992-A7DF-4603-AA38-5D939A6F098EQ41546370-AC9D6993-711B-4316-8674-CD9EDA2A8FB0
P2860
The mechanism of action of glatiramer acetate treatment in multiple sclerosis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The mechanism of action of glatiramer acetate treatment in multiple sclerosis.
@en
The mechanism of action of glatiramer acetate treatment in multiple sclerosis.
@nl
type
label
The mechanism of action of glatiramer acetate treatment in multiple sclerosis.
@en
The mechanism of action of glatiramer acetate treatment in multiple sclerosis.
@nl
prefLabel
The mechanism of action of glatiramer acetate treatment in multiple sclerosis.
@en
The mechanism of action of glatiramer acetate treatment in multiple sclerosis.
@nl
P1433
P1476
The mechanism of action of glatiramer acetate treatment in multiple sclerosis
@en
P2093
Amy E Lovett-Racke
Michael K Racke
P304
P356
10.1212/WNL.0B013E3181C97E39
P407
P478
74 Suppl 1
P577
2010-01-01T00:00:00Z